Introducing RESONIC™

Introducing RESONIC™ Soliton, Inc. Rolls Out Its Rapid Acoustic Pulse™ Technology with a Multi-Platform Device Indicated for Tattoo Removal and Cellulite Treatment with First Shipments in June HOUSTON, May 5, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced the launch of its highly anticipated Rapid Acoustic Pulse™ (RAP) device — RESONIC™. The dual-platform RESONIC™ device utilizes a first-of-its-kind technology and offers a paradigm-shifting approach to two in-demand procedures: tattoo removal and cellulite treatment. Harnessing the power of sound, RESONIC helps achieve 75% greater fading of tattoos in as few as 3 sessions and improves the appearance of cellulite non-invasively with high patient satisfaction after just 1 treatment session. "This is an exciting day for Soliton and the RESONIC brand," shared Brad Hauser, President & CEO of Soliton. "It's been a long time in the making and we're excited to finally bring this innovative and efficacious solution to procedures that have had historically low patient satisfaction or required numerous treatment sessions to achieve expected results. Launching RESONIC with two unique indications has been a strategic goal of ours since receiving our first FDA clearance in 2019. This approach enables our HCP partners to drive multiple revenue streams among two different patient profiles with one device, positioning our partners for accelerated practice growth, and poising RESONIC to become a leading aesthetics brand," added Hauser. Leveraging its proprietary technology, the RESONIC device is designed to safely deliver rapid, high-pressure acoustic shockwaves at a rate of up to 100 pulses per second, resulting in the physical change of targeted cellular structures without creating cavitation or heating that could result in surrounding tissue damage. The Rapid Acoustic Pulse technology creates a new